A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial

Lucia Masarova; Brandi N. Reeves; Firas El Chaer; Lynda Foltz; Tsewang Tashi; Ghaith Abu-Zeinah; Jennifer Lucas; Anna B. Halpern; Dawn Maze; Albert Qin; Hana Safah; Fengshuo Lan; Casey L. O'Connell; Swati Goel; Lindsay Rein; Bruno Fang; Joan How; Sunil Babu; Zhuoyan Li; Sonia Cerquozzi; Stephen T. Oh; Anthony M. Hunter; Nikolai Podoltsev; Pankit Vachhani; Abdulraheem Yacoub; Julia M. Cunningham; Christopher Hillis; Salman Otoukesh; Oleh Zagrijtschuk; Henry Castro; Prithviraj Bose

doi:10.3389/fmed.2025.1548590

A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial

Lucia Masarova
, Brandi N. Reeves
, Firas El Chaer
, Lynda Foltz
, Tsewang Tashi
, Ghaith Abu-Zeinah
, Jennifer Lucas
, Anna B. Halpern
, Dawn Maze
, Albert Qin
, Hana Safah
, Fengshuo Lan
, Casey L. O'Connell
, Swati Goel
, Lindsay Rein
, Bruno Fang
, Joan How
, Sunil Babu
, Zhuoyan Li
, Sonia Cerquozzi

Stephen T. Oh, Anthony M. Hunter, Nikolai Podoltsev, Pankit Vachhani, Abdulraheem Yacoub, Julia M. Cunningham, Christopher Hillis, Salman Otoukesh, Oleh Zagrijtschuk, Henry Castro, Prithviraj Bose

Medical Oncology

University of Texas MD Anderson Cancer Center
University of North Carolina at Chapel Hill
University of Virginia
University of British Columbia
University of Utah
Cornell University
Marin Cancer Care
University of Washington
Princess Margaret Cancer Centre
PharmaEssentia Corporation
Our Lady of the Lake Regional Medical Center
University of Southern California
Albert Einstein College of Medicine
Duke University
Astera Cancer Care
Massachusetts General Hospital
Fort Wayne Medical Oncology & Hematology
Greater Baltimore Medical Center
University of Calgary
Washington University St. Louis
Emory University
Yale University
University of Alabama at Birmingham
University of Kansas
MedStar Georgetown University Hospital
McMaster University
City of Hope National Med Center
PharmaEssentia USA Corporation
Everest Clinical Research

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Original language	English
Article number	1548590
Journal	Frontiers in Medicine
Volume	12
DOIs	https://doi.org/10.3389/fmed.2025.1548590
State	Published - 2025

Keywords

clinical trial
complete hematologic response
essential thrombocythemia (ET)
higher initial dose and accelerated titration (HDAC) regimen
molecular response
ropeginterferon alfa-2b-njft (ropeg)

Access to Document

10.3389/fmed.2025.1548590

Cite this

Masarova, L., Reeves, B. N., El Chaer, F., Foltz, L., Tashi, T., Abu-Zeinah, G., Lucas, J., Halpern, A. B., Maze, D., Qin, A., Safah, H., Lan, F., O'Connell, C. L., Goel, S., Rein, L., Fang, B., How, J., Babu, S., Li, Z., ... Bose, P. (2025). A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial. Frontiers in Medicine, 12, Article 1548590. https://doi.org/10.3389/fmed.2025.1548590

@article{c05bd854eebc4a54817d6f4a1391c330,

title = "A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial",

keywords = "clinical trial, complete hematologic response, essential thrombocythemia (ET), higher initial dose and accelerated titration (HDAC) regimen, molecular response, ropeginterferon alfa-2b-njft (ropeg)",

author = "Lucia Masarova and Reeves, \{Brandi N.\} and \{El Chaer\}, Firas and Lynda Foltz and Tsewang Tashi and Ghaith Abu-Zeinah and Jennifer Lucas and Halpern, \{Anna B.\} and Dawn Maze and Albert Qin and Hana Safah and Fengshuo Lan and O'Connell, \{Casey L.\} and Swati Goel and Lindsay Rein and Bruno Fang and Joan How and Sunil Babu and Zhuoyan Li and Sonia Cerquozzi and Oh, \{Stephen T.\} and Hunter, \{Anthony M.\} and Nikolai Podoltsev and Pankit Vachhani and Abdulraheem Yacoub and Cunningham, \{Julia M.\} and Christopher Hillis and Salman Otoukesh and Oleh Zagrijtschuk and Henry Castro and Prithviraj Bose",

year = "2025",

doi = "10.3389/fmed.2025.1548590",

language = "English",

volume = "12",

journal = "Frontiers in Medicine",

issn = "2296-858X",

}

Masarova, L, Reeves, BN, El Chaer, F, Foltz, L, Tashi, T, Abu-Zeinah, G, Lucas, J, Halpern, AB, Maze, D, Qin, A, Safah, H, Lan, F, O'Connell, CL, Goel, S, Rein, L, Fang, B, How, J, Babu, S, Li, Z, Cerquozzi, S, Oh, ST, Hunter, AM, Podoltsev, N, Vachhani, P, Yacoub, A, Cunningham, JM, Hillis, C, Otoukesh, S, Zagrijtschuk, O, Castro, H & Bose, P 2025, 'A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial', Frontiers in Medicine, vol. 12, 1548590. https://doi.org/10.3389/fmed.2025.1548590

TY - JOUR

T1 - A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada

T2 - EXCEED-ET trial

AU - Masarova, Lucia

AU - Reeves, Brandi N.

AU - El Chaer, Firas

AU - Foltz, Lynda

AU - Tashi, Tsewang

AU - Abu-Zeinah, Ghaith

AU - Lucas, Jennifer

AU - Halpern, Anna B.

AU - Maze, Dawn

AU - Qin, Albert

AU - Safah, Hana

AU - Lan, Fengshuo

AU - O'Connell, Casey L.

AU - Goel, Swati

AU - Rein, Lindsay

AU - Fang, Bruno

AU - How, Joan

AU - Babu, Sunil

AU - Li, Zhuoyan

AU - Cerquozzi, Sonia

AU - Oh, Stephen T.

AU - Hunter, Anthony M.

AU - Podoltsev, Nikolai

AU - Vachhani, Pankit

AU - Yacoub, Abdulraheem

AU - Cunningham, Julia M.

AU - Hillis, Christopher

AU - Otoukesh, Salman

AU - Zagrijtschuk, Oleh

AU - Castro, Henry

AU - Bose, Prithviraj

PY - 2025

Y1 - 2025

KW - clinical trial

KW - complete hematologic response

KW - essential thrombocythemia (ET)

KW - higher initial dose and accelerated titration (HDAC) regimen

KW - molecular response

KW - ropeginterferon alfa-2b-njft (ropeg)

UR - https://www.scopus.com/pages/publications/105004648510

U2 - 10.3389/fmed.2025.1548590

DO - 10.3389/fmed.2025.1548590

M3 - Article

AN - SCOPUS:105004648510

SN - 2296-858X

VL - 12

JO - Frontiers in Medicine

JF - Frontiers in Medicine

M1 - 1548590

ER -

A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial

Keywords

Access to Document

Other files and links

Fingerprint

Cite this